Mithra Pharmaceuticals Sa (MITRA)

Brussels
Currency in EUR
0.22
0.00(0.00%)
Real-time Data·
Showing Mithra Pharmaceuticals Sa historical data. For real-time data please try another search
Fair Value
Day's Range
0.220.22
52 wk Range
0.200.29
Key Statistics
Edit
Prev. Close
0.22
Open
0.22
Day's Range
0.22-0.22
52 wk Range
0.2-0.29
Volume
-
Average Volume (3m)
82.34K
1-Year Change
1.85%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MITRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Mithra Pharmaceuticals Sa News & Analysis

Show more

Mithra Pharmaceuticals Sa Company Profile

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Employees
270
Market
Belgium

Compare MITRA to Peers and Sector

Metrics to compare
MITRA
Peers
Sector
Relationship
P/E Ratio
0.0x−6.4x−0.5x
PEG Ratio
0.00−0.040.00
Price/Book
0.0x1.0x2.6x
Price / LTM Sales
0.0x3.2x3.1x
Upside (Analyst Target)
0.0%145.6%48.3%
Fair Value Upside
Unlock6.0%7.6%Unlock

Earnings

Latest Release
Mar 08, 2024
EPS / Forecast
-- / --
Revenue / Forecast
33.12M / --
EPS Revisions
Last 90 days

MITRA Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.